Recent Insights » Articles » Assessing Cardiac Safety in Oncology Drug Development
×

Access Whitepaper

First Name
Last Name
Company
Thank you!
Error - something went wrong!
   

Assessing Cardiac Safety in Oncology Drug Development

July 11, 2019 Jonathan Seltzer, MD, MBA, MA, FACC

Based on a Cardiac Safety Research Consortium Think Tank held in October 2017 on “Detection, Assessment, and Risk Mitigation of Cardiac Safety Signals in Oncology Drug Development, this publication discusses emerging cardio-oncology nuances and the latest regulatory thinking on ways to manage risks. 

Previous Flipbook
Placebo Response Reduction
Placebo Response Reduction

WCG has developed and validated the industry-leading Placebo Response Reduction training program.

Next Flipbook
Lack of Training Compromises Trial Results, Expert Says
Lack of Training Compromises Trial Results, Expert Says

At its very core, a clinical trial is a measurement system; yet, the industry has not focused enough on tra...

Request a Genetics in Clinical Trials training session

What You'll Learn
Return to Home